Radioactive drug targets brain cancer in early trial

NCT ID NCT05450744

First seen Jan 24, 2026 · Last updated May 16, 2026 · Updated 17 times

Summary

This early-stage study tests a radioactive drug called 131I-TLX101 given alongside standard treatments for people with newly diagnosed glioblastoma, an aggressive brain cancer. The main goal is to find a safe dose and check for side effects. About 12 adults who have had surgery for glioblastoma will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Gold Coast University Hospital

    RECRUITING

    Gold Coast, Queensland, 4215, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut für Nuklearmedizin und Endokrinologie

    RECRUITING

    Linz, Austria

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Olivia Newton John Cancer Research Institute/Austin Health

    RECRUITING

    Melbourne, Victoria, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Royal Adelaide Hospital

    RECRUITING

    Adelaide, South Australia, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Royal North Shore Hospital

    RECRUITING

    Sydney, New South Wales, 2065, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • UNMC Utrecht

    RECRUITING

    Utrecht, 3051, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.